Potential weight loss of 15-25 pounds within 2 months, and up to 25-50 pounds or more in 4 months
Compounded formulas that may relieve side effects such as nausea
Weekly injections
Option to repeat the program as many times as you wish
Common Side Effects
Nausea
Constipation
Heartburn
Risk of Thyroid c-cell Tumors
Individuals or family members diagnosed with
Multiple Endocrine Neoplasia Syndrome Type 2 or
medullary thyroid cancer should not take Semaglutide
Information
Semaglutide stimulates a natural hormone that impacts hunger
and fullness sensations, leading to reduced cravings and
weight loss. During a clinical trial involving 2,000 individuals from 16
different countries, those who received weekly injections of Semaglutide
lost an average of 15% of their body weight, compared to just a 3% loss in
the placebo group.
NOT BEING OFFERED RIGHT NOW TAKEN OFF SHORTAGE LIST 10/02/24 BY FDA
Benefits
Reduce appetite and cravings
leading to weight loss
The results from clinical trials have demonstrated a significant reduction in weight, ranging from 15% to 30%, based on the dose prescribed.
To minimize the occurrence of side effects, such as nausea, the medication is compounded with specific formulas.
The injections are administered once a week
Can repeat the program as many times as necessary to achieve desired weight loss goals
Common Side Effects
Nausea
Constipation
Indigestion
Risk of Thyroid c-cell Tumors
Individuals or family members diagnosed with
Multiple Endocrine Neoplasia Syndrome Type 2 or
medullary thyroid cancer should not take Semaglutide
Information
Tirzepatide is a medication that targets two receptors in the brain responsible for regulating food intake and appetite. It works by combining the actions of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). In a clinical trial involving 2,539 adults, the use of Tirzepatide resulted in weight loss ranging from 15% to 35% compared to the placebo group.
